Valuation: Ind-Swift Laboratories Limited

Market Cap 11.4B 120M 104M 96.77M 89M 168M 170M 1.14B 446M 5.7B 450M 440M 18.89B P/E 2024
1.41x
P/E 2025 2.38x
Enterprise Value 7.13B 74.99M 64.95M 60.55M 55.69M 105M 106M 712M 279M 3.57B 282M 275M 11.82B EV / Sales 2024
0.14x
EV / Sales 2025 0.12x
Free-Float
40.72%
Yield 2024 *
-
Yield 2025 -
1 day-1.23%
1 week+3.83%
Current month+1.42%
1 month+2.84%
3 months+57.84%
6 months+73.12%
Current year+158.53%
1 week 215.5
Extreme 215.5
237.45
1 month 213.15
Extreme 213.15
248
Current year 88.5
Extreme 88.5
248
1 year 87
Extreme 87
248
3 years 67.15
Extreme 67.15
248
5 years 51.1
Extreme 51.1
248
10 years 15.25
Extreme 15.25
248
Manager TitleAgeSince
Chief Executive Officer 74 04/01/1995
Chief Executive Officer 44 15/06/2011
Director of Finance/CFO - 29/09/2018
Director TitleAgeSince
Director/Board Member 44 -
Chairman 74 -
Director/Board Member 35 23/03/2010
Change 5-day change 1-year change 3-year change Capi.($)
-1.23%+3.83% - - 211M
+0.85%-2.21%+22.67%+68.57% 48.95B
+3.09%+7.65%+60.81%+132.38% 39.36B
+1.23%+0.71%-0.67%+20.69% 12.39B
-1.31%-0.77%+18.63%+68.88% 11.76B
-0.29%-0.38%+30.75%+134.53% 9.14B
-0.08%+2.90%+18.08%+33.63% 7.05B
+1.61%-4.86%+36.73%-14.17% 6.86B
+0.28%+3.42%+11.83%+177.61% 6.7B
+0.79%+3.84%-29.57%+15.81% 5.67B
Average +0.49%-0.26%+18.81%+70.88% 16.43B
Weighted average by Cap. +1.20%-0.33%+28.98%+83.06%

Financials

2024 2025
Net sales 12.97B 136M 118M 110M 101M 191M 193M 1.29B 508M 6.49B 512M 501M 21.5B 5.62B 59.07M 51.16M 47.69M 43.87M 82.81M 83.74M 560M 220M 2.81B 222M 217M 9.31B
Net income 4.21B 44.27M 38.34M 35.74M 32.87M 62.06M 62.75M 420M 165M 2.11B 166M 163M 6.98B 2.5B 26.34M 22.81M 21.27M 19.56M 36.93M 37.34M 250M 98.09M 1.25B 98.93M 96.75M 4.15B
Net Debt -4.15B -43.68M -37.83M -35.26M -32.43M -61.23M -61.91M -414M -163M -2.08B -164M -160M -6.88B -4.27B -44.86M -38.85M -36.22M -33.31M -62.88M -63.59M -426M -167M -2.13B -168M -165M -7.07B
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,246
Date Price Change Volume
06/08/26 228.00 -1.23% 28,141
05/08/26 ₹230.85 +0.13% 18,980
04/08/26 ₹230.55 +1.16% 16,024
03/08/26 ₹227.90 +1.38% 13,020
31/07/26 ₹224.80 +2.37% 30,540